Clinical Trials
5
Active:0
Completed:4
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (50.0%)Phase 1
1 (25.0%)Phase 2
1 (25.0%)Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer FemaleHormone Receptor Positive Malignant Neoplasm of Breast
- Interventions
- Drug: Endocrine therapy
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Kyoto Breast Cancer Research Network
- Target Recruit Count
- 141
- Registration Number
- NCT03969121
- Locations
- 🇦🇺
Monash Health, Clayton, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
🇭🇰UNIMED Medical Institute, Hong Kong, Hong Kong
Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- Drug: Durvalmab&Tremelimumab&Fulvestrant
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Kyoto Breast Cancer Research Network
- Target Recruit Count
- 1
- Registration Number
- NCT03430466
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: Cohort A
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Kyoto Breast Cancer Research Network
- Target Recruit Count
- 32
- Registration Number
- NCT03430479
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
News
No news found